Largest pharmaceutical companies in the United States by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 24 pharmaceutical companies in the United States ranked by total debt, at NOK 659.2B, ahead of Pfizer (NOK 632.8B) and Merck & Co (NOK 481.5B). Figures as of 20 Nov 2026, 16:48 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AbbVieNOK 659.2B
- Median
- NOK 22.4B
- Combined market value
- NOK 36.77T
- Countries
- 1
- Not ranked
- 20no total debt on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | NOK 659.2B | NOK 4.99T | NOK 2,820.69 | 1.86% up | 20% up | ||
| 2 | PfizerPFE · Health Care | NOK 632.8B | NOK 1.54T | NOK 269.60 | 0.24% up | 10% up | ||
| 3 | Merck & CoMRK · Health Care | NOK 481.5B | NOK 3.26T | NOK 1,320.74 | 1.83% up | 36% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | NOK 468.2B | NOK 6.37T | NOK 2,645.19 | 1.39% up | 31% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | NOK 440.6B | NOK 1.19T | NOK 580.41 | 1.87% up | 26% up | ||
| 6 | Eli LillyLLY · Health Care | NOK 415.1B | NOK 11.79T | NOK 13,230.66 | 0.27% up | 28% up | ||
| 7 | ViatrisVTRS · Health Care | NOK 140.7B | NOK 218.3B | NOK 190.44 | 1.91% down | 90% up | ||
| 8 | Abbott LaboratoriesABT · Health Care | NOK 126.3B | NOK 1.76T | NOK 1,017.16 | 0.27% up | 19% down | ||
| 9 | ZoetisZTS · Health Care | NOK 88.3B | NOK 320.3B | NOK 788.38 | 0.08% down | 34% down | ||
| 10 | Royalty PharmaRPRX · Health Care | NOK 87.4B | NOK 384.2B | NOK 668.11 | 1.02% up | 74% up | ||
| 11 | Elanco Animal HealthELAN · Health Care | NOK 39.2B | NOK 126.4B | NOK 252.80 | 1.54% down | 18% up | ||
| 12 | Amneal PharmaceuticalsAMRX · Health Care | NOK 25.1B | NOK 71.8B | NOK 206.07 | 1.36% down | 79% up | ||
| 13 | BridgeBio PharmaBBIO · Health Care | NOK 19.6B | NOK 147B | NOK 754.84 | 1.14% down | 15% up | ||
| 14 | Regeneron PharmaceuticalsREGN · Health Care | NOK 19.4B | NOK 941.1B | NOK 9,097.33 | 0.99% up | 22% up | ||
| 15 | Ionis PharmaceuticalsIONS · Health Care | NOK 17.7B | NOK 44.7B | NOK 268.67 | 1.07% up | 64% down | ||
| 16 | InsmedINSM · Health Care | NOK 5.3B | NOK 311.8B | NOK 1,421.09 | 0.73% up | 27% down | ||
| 17 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 3.3B | NOK 88.5B | NOK 3,808.41 | 1.71% down | 28% down | ||
| 18 | Legend BiotechLEGN · Health Care | NOK 3.1B | NOK 29.6B | NOK 152.35 | 3.11% down | 43% down | ||
| 19 | CytokineticsCYTK · Health Care | NOK 2.8B | NOK 70.4B | NOK 505.31 | 0.54% up | 21% down | ||
| 20 | TG TherapeuticsTGTX · Health Care | NOK 2.4B | NOK 95.2B | NOK 630.11 | 0.56% down | 103% up | ||
| 21 | Cogent BiosciencesCOGT · Health Care | NOK 2.2B | NOK 46.2B | NOK 265.35 | 2.05% down | 25% down | ||
| 22 | Axsome TherapeuticsAXSM · Health Care | NOK 1.8B | NOK 67B | NOK 1,273.62 | 3.88% down | 9% down | ||
| 23 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 1.1B | NOK 76.6B | NOK 1,104.61 | 3.16% down | 15% up | ||
| 24 | Definium TherapeuticsDFTX · Health Care | NOK 396.3M | NOK 38.9B | NOK 284.30 | 1.26% down | 176% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7663 NOK). 20 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States rank first by total debt?
AbbVie (NOK 659.2B), Pfizer (NOK 632.8B) and Merck & Co (NOK 481.5B) are the top three of the 24 pharmaceutical companies in the United States ranked by total debt as of 20 Nov 2026, 16:48 UTC.
How many pharmaceutical companies in the United States are in this ranking?
24 are ranked by total debt. 20 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 24 pharmaceutical companies in the United States ranked by total debt have a combined market value of NOK 36.77T as of 20 Nov 2026, 16:48 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total debt”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.